Home
    • Plans Blog Contact
    Elanco Animal Health Inc logo

    Elanco Animal Health Inc

    ELAN
    Last price US$23.68
    Market cap US$12.4b
    12M price change 31.63%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Elanco Animal Health Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Elanco Animal Health Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Revenue was $1,368M (reported); EPS was $0.34 (reported).

    Revenue $1,368M reported
    EPS $0.34 reported
    Net income $54M reported
    Adjusted EBITDA $288M reported

    What changed

    • Revenue reported to $1,368M; EPS reported to $0.34.

    Guidance / outlook

    The company anticipates a tailwind to revenue of approximately $60 million from the favorable impact of foreign exchange rates compared to prior year.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q FOR THE PERIOD ENDED JUNE 30, 2026 Aug 05, 2026 SEC filing 8-K DATED AUGUST 5, 2026 Aug 05, 2026 Earnings release EXHIBIT 99.1 PRESS RELEASE DATED MAY 6, 2026 May 06, 2026 SEC filing 10-Q FOR THE PERIOD ENDED MARCH 31, 2026 May 06, 2026 SEC filing 8-K DATED MAY 6, 2026 May 06, 2026 SEC filing 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 Feb 24, 2026 SEC filing 8-K DATED FEBRUARY 24, 2026 Feb 24, 2026 Earnings release EXHIBIT 99.1 PRESS RELEASE DATED FEBRUARY 24, 2026 Feb 24, 2026 Earnings release EXHIBIT 99.1 PRESS RELEASE DATED NOVEMBER 5, 2025 Nov 05, 2025 SEC filing 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2025 Nov 05, 2025 SEC filing 8-K DATED NOVEMBER 5, 2025 Nov 05, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Elanco Animal Health Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.17/5
    Elanco Animal Health Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Elanco Anima... ELAN US$12.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.24/5
    Elanco Animal Health Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Elanco Anima... ELAN US$12.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 1.86/5
    Elanco Animal Health Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Elanco Anima... ELAN US$12.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Elanco Animal Health Inc logo

    Elanco Animal Health Inc

    US$23.68

    US$0.42

    -98.2% vs price

    US$12.4b

    7.10%

    31.63%